

**SCIENTIFIC ADVISORY COMMITTEE ON ALTERNATIVE
TOXICOLOGICAL METHODS (SACATM)
Preliminary Agenda**

Hilton Arlington
950 North Stafford Street, Arlington, VA 22203
June 16 – 17, 2011

JUNE 16

| | | |
|----------|---|---|
| 8:30 AM | Introductions | Dr. Steven Niemi, Massachusetts General Hospital, SACATM Chair |
| 8:40 | Welcome and Opening Remarks | Dr. Linda Birnbaum, NIEHS/NTP Dr. John Bucher, NIEHS/NTP Dr. Jodie Kulpa-Eddy, USDA, ICCVAM Chair |
| 9:10 | Welcome and NICEATM-ICCVAM Update <ul style="list-style-type: none">• NICEATM-ICCVAM Activities• Regulatory Acceptance and Availability of ICCVAM-Recommended Alternative Test Methods• Public Comments• SACATM Discussion | Dr. William Stokes, NIEHS/NTP Dr. Niemi |
| 10.00 | BREAK | |
| 10:30 | Report on Peer Review Panel Meeting: Evaluation of an <i>In Vitro</i> Estrogen Receptor Transcriptional Activation Test Method for Endocrine Disruptor Chemical Screening <ul style="list-style-type: none">• Introduction and Overview of Proposed Methods and Applications• Overview of Panel Report• Public Comments• SACATM Discussion | Dr. Warren Casey, NIEHS/NTP Dr. John Vandenberg, Panel Chair, NC State Dr. Niemi |
| 12:00 PM | LUNCH | |
| 1:00 | Federal Agency Research, Development, Translation, and Validation Activities Relevant to the NICEATM-ICCVAM Five-Year Plan: NIH Update <ul style="list-style-type: none">• Introduction• NIH Research Progress and Priorities• SBIR Grants and Contracts• Public Comments• SACATM Discussion | Dr. Margaret Snyder, NIH TBD Dr. Daniel Shaughnessy, NIEHS Dr. Niemi |
| 2:30 | BREAK | |
| 3:00 | Nominations to ICCVAM (ACTION) <ul style="list-style-type: none">• Introduction• <i>In Vitro</i> Pyrogen Assay Validation• Public Comments• SACATM Discussion and Vote• Botulinum <i>In Vitro</i> Assays• Public Comments• SACATM Discussion and Vote | Dr. Kulpa-Eddy Dr. Thomas Hartung, Biotest AG Dr. Niemi Dr. Ward Tucker, Biosentinel Inc. Dr. Niemi |
| 4:30 | Report from the ICCVAM Workshop Series on Best Practices for Regulatory Safety Testing <ul style="list-style-type: none">• Assessing the Potential for Chemically Induced Eye Injuries• Assessing the Potential for Chemically Induced Allergic Contact Dermatitis• Public Comments• SACATM Discussion | Dr. Jill Merrill, FDA Dr. Joanna Matheson, CPSC, ICCVAM Vice-chair Drs. Eugene Elmore, University of California - Irvine and Michael Olson, GlaxoSmithKline |

5:30 ADJOURN Dr. Niemi

JUNE 17

| | | |
|----------|---|---|
| 8:30 AM | Introductions | Dr. Niemi |
| 8:40 | Report and Recommendations from the International Workshop on Alternative Methods to Reduce, Refine, and Replace the Use of Animals in Vaccine Potency Testing: State of the Science and Future Directions <ul style="list-style-type: none">• Public Comments• SACATM Discussion | Dr. Kulpa-Eddy Dr. Richard McFarland, FDA Dr. Niemi |
| 10:00 | BREAK | |
| 10:30 | Updates on International Collaborations <ul style="list-style-type: none">• Korean Center for the Validation of Alternative Methods• Health Canada• Japanese Center for the Validation of Alternative Methods• European Centre for the Validation of Alternative Methods | Dr. Soojung Sohn, KoCVAM Mr. Michael Inskip, Health Canada Dr. Hajime Kojima, JaCVAM Dr. Joachim Kreysa, ECVAM |
| 12:00 PM | Other Business | Dr. Niemi |
| 12:15 | ADJOURN | Dr. Niemi |

Preliminary Draft June 3, 2011